Latest Regulatory News

SkyCity Entertainment Group posted a solid half-year profit increase to NZD 12.1 million despite a slight revenue dip, bolstered by a major equity raise and a clean bill on its Adelaide casino licence.

Auckland International Airport reported a 6% rise in underlying profit for the first half of FY26, driven by passenger growth and key infrastructure projects. The airport also narrowed its full-year guidance while navigating global fleet capacity challenges.

MEC Resources Ltd reported a half-year loss of $431,971 amid ongoing legal challenges over key gas exploration permits, while progressing investments in clean energy and neurotechnology. The company also completed a $359K options placement, reinforcing its financial position.

Infragreen Group Limited reports a remarkable turnaround with a statutory net profit of A$3.64 million for H1 2025 and declares its inaugural interim dividend, underscoring confidence in its sustainable infrastructure investments.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.

Bell Financial Group delivered a robust 17.1% rise in net profit after tax to $36 million for 2025, driven by strong growth in its Platforms division and a rebound in market activity. The company declared a fully franked final dividend of 6.5 cents per share, signalling confidence as it prepares to launch a new wealth management platform in 2026.

Kaili Resources has reported encouraging initial pXRF results from its latest aircore drilling campaign targeting rare earth elements in South Australia's Mallee Project. Full assay results are pending, setting the stage for expanded exploration.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

IDT Australia Limited has reported a significant narrowing of its half-year loss to $1.3 million, driven by stable revenues and operational efficiencies. The pharmaceutical manufacturer highlights growth in key segments despite some timing setbacks.

Aeris Resources has withdrawn aspirational statements about extending mine life at its Tritton and Jaguar operations following its Peel Resources acquisition announcement, urging investors to exercise caution.

Solvar Limited reported a 5.8% rise in half-year NPAT to $20 million, driven by the sale of its New Zealand written-off loan book and expanded debt facilities. The company also announced a special dividend and outlined growth plans in commercial lending.